SOD1 and amyotrophic lateral sclerosis: However, there is an emerging line of therapeutics to treat ALS via the selective manipulation of aberrant genes using antisense oligonucleotides (ASOs), including the recent FDA-approved Tofersen, which lowers SOD1 mRNA and slows clinical decline with earlier treatment initiation [14–16].